|
Impact of dose reductions on clinical outcomes among patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in oncology clinics in the United States. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst) |
|
|
Honoraria - Coherus BioSciences; Coherus BioSciences; Coherus BioSciences; Coherus BioSciences; Helsinn Healthcare; Helsinn Healthcare; Helsinn Healthcare; Helsinn Healthcare; HERON; HERON; HERON; HERON; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer |
Consulting or Advisory Role - Coherus BioSciences; Coherus BioSciences; Coherus BioSciences; Coherus BioSciences; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Ipsen; Ipsen; Ipsen; Ipsen; Tocagen; Tocagen; Tocagen; Tocagen |
Speakers' Bureau - Helsinn Healthcare; Helsinn Healthcare; Helsinn Healthcare; Helsinn Healthcare; HERON; HERON; HERON; HERON; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer |
Research Funding - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Celgene; Celgene; Celgene; Celgene |
Travel, Accommodations, Expenses - Coherus BioSciences; Coherus BioSciences; Coherus BioSciences; Coherus BioSciences; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Helsinn Healthcare; Helsinn Healthcare; Helsinn Healthcare; Helsinn Healthcare; HERON; HERON; HERON; HERON; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer; Tocagen; Tocagen; Tocagen; Tocagen |
|
|
Employment - Flatiron Health; Flatiron Health; Flatiron Health; Flatiron Health |
Stock and Other Ownership Interests - Flatiron Health; Flatiron Health; Flatiron Health; Flatiron Health; Roche; Roche; Roche; Roche |
Consulting or Advisory Role - Advanced Medical; Advanced Medical; Advanced Medical; Advanced Medical; Grand Rounds (I); Grand Rounds (I); Grand Rounds (I); Grand Rounds (I); InfiniteMD; InfiniteMD; InfiniteMD; InfiniteMD |
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst) |
Other Relationship - De Luca Foundation; De Luca Foundation; De Luca Foundation; De Luca Foundation |